Cefiderocol, sold as Fetroja, is a cephalosporin antibiotic designed to enter Gram-negative bacteria through their own iron-uptake systems. Three recent developments make it worth a fresh look: the Infectious Diseases Society of America (IDSA) published a new edition of its resistant Gram-negative guidance on 30 July 2026; the US prescribing information for Fetroja was revised in July 2026; and the Indian Council of Medical Research (ICMR) continues to report rising carbapenem resistance in Indian tertiary-care hospitals. This article summarises what those sources and the pivotal trials state, for hospital pharmacists, microbiology and infection-control teams, and procurement departments.
Topics
